Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
March 14, 2023 16:35 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders
March 01, 2023 06:00 ET
|
Yasheng Group
San Jose, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders; Begins Raising Capital for our Subsidiary, Jove Pharmaceutics...
Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development
February 24, 2023 03:30 ET
|
Yasheng Group
San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February 24, 2023) - Yasheng Group, (OTC:...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Participate in Two Upcoming Virtual Conferences
September 28, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
August 06, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 ...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2020 16:06 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...